Do you offer local consolidative therapy for patients with polymetastatic driver mutation-positive NSCLC who respond well to targeted therapy?

Topics: Radiation Oncology • Thoracic Malignancies • Medical Oncology • MD Anderson • NCI-CCC Tumor Board Question • Non-small cell lung cancer • NCI-CCC Thoracic Tumor Board Question

If so, when and to what extent?

Answer from: Medical Oncologist at Academic Institution

This is a great question. In phase II prospective study, Gomez and colleagues (Gomez et al., PMID 31067138) demonstrated a PFS and OS benefit with local consolidative therapy in patients whose disease did not progress after first-line systemic therapy. In my opinion, local consolidation therapy to o...

Comments

Radiation Oncologist at National Cancer Institute
The question was about polymetastatic, driver-muta...

Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
@Vik is right. There is a paucity of data to guide...

Answer from: Radiation Oncologist at Academic Institution

For truly polymetastatic patients, I tend to take an approach of consolidation of oligoprogressive or oligoresistant lesions while these patients continue on highly effective systemic therapy. Driver mutations adenos can have durable responses to generally well-tolerated therapy for many years and w...

Related Questions